Paul J Lynch MD PLLC

Paul J Lynch MD PLLC, a for-profit medical services partnership based in Scottsdale, Arizona, delivers expert witness and medical consultation services to the Drug Enforcement Administration and Department of Justice components as a prime contractor, competing without set-aside designation in the open market. The firm operates exclusively as a prime (100% of recent awards), with no subcontractor relationships in the source data.

The vendor's capability footprint is tightly focused on medical-legal consulting for controlled-substance enforcement. Services include comprehensive medical record reviews, analysis of Controlled Substance Prescription Monitoring Program (CSPMP) data, expert report writing, and expert witness testimony in administrative hearings and legal proceedings. Representative recent awards include a $44,200 time-and-materials purchase order from DOJ's Criminal Division for expert witness and medical consultation services (awarded September 2025), a $91,200 labor-hours purchase order from DEA for subject-matter expert review of patient files and CSPMP data with report composition and pre-hearing preparation (awarded November 2023), and a $31,658 time-and-materials purchase order from U.S. Attorney's Offices for expert witness services (awarded November 2024). Performance locations span multiple federal jurisdictions: Salt Lake City, Seattle, Scottsdale, Portland, Los Angeles, Washington DC, and other domestic sites where investigations and administrative hearings occur.

Customer concentration is extreme and persistent. DEA accounts for 36 of 42 awards (86% of the portfolio) and $682 thousand of $941 thousand combined potential value, with U.S. Attorney's Offices providing 4 awards and $111 thousand, DOJ Civil Division 1 award and $104 thousand, and DOJ Criminal Division 1 award and $44 thousand. The top four customer agencies represent 100% of recent awards and dollars. The vendor does not compete across multiple agencies or use government-wide contract vehicles; all work flows through direct purchase orders from DOJ components.

Activity has grown from 5 awards annually in 2022 to 12 in 2024, then softened to 8 in 2025 and 6 in the first quarter of 2026. Ten awards with ultimate completion dates in the next twenty-four months carry combined potential value of $218 thousand, representing recompete exposure at roughly 23% of the current portfolio. Combined dollars obligated across all awards total $918 thousand against $941 thousand potential value, indicating 98% invoicing realization.

The vendor operates at sub-million award scale with labor-hours and time-and-materials pricing structures, positioning as a solo practitioner medical expert rather than a scalable services firm. Absence of subcontractor relationships or employee-FTE context in the source suggests Dr. Lynch functions as the primary service delivery resource. Category concentration data indicates 23 awards classified under General Medical and Surgical Hospitals NAICS and 32 awards under "Support - Professional: Expert Witness" PSC codes, reflecting the narrow scope of the practice.